RPTX 250117 7.50C (RPTX250117C7500) Stock Options, News & Quotes

0.05
0.000.00%

15min DelayTrading Dec 13 11:19 ET

0.00High0.00Low

SymbolStock Name

PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

WciStudios

Dec 13 13:26

$Repare Therapeutics (RPTX.US)$ lets crack 1.80 and at least hold

WciStudios

Dec 13 13:23

$Repare Therapeutics (RPTX.US)$

Trytosaveabit

Dec 13 08:03

Only posting this update because it validates what I said yesterday that results/data don’t justify the huge drop!

$Repare Therapeutics (RPTX.US)$ Repare Therapeutics Reports Positive Data From MYTHIC Phase 1 Trial And Plans For Phase 3 In 2025
Repare Therapeutics Inc. (RPTX), a clinical-stage precision oncology company, presented encouraging updates from its MYTHIC Phase 1 clinical trial and outlined its plans for future registrational trials.
MYTHIC is a phase I dose expansion clinical trial eva...

Jaguar8

Dec 12 19:10

🕗Watchlist FRIDAY December 13. NFA. Tired now so I’ll attach the watchlist for Thursday and Wednesday and check those which didn’t run yet. Remember it’s our lucky day tomorrow: Friday 13th

NOTE: Whenever a stock is up, make sure you check its dilution risk - cash on hand because most likely if they are cash-strapped, they will make offering. Scaling out is key. NEVER listen to those who say hold on because if you lose money, they wouldnt care AT ALL.
*************************************
REVERSE...

Jaguar8

Dec 12 15:20

NEWS

$Repare Therapeutics (RPTX.US)$
Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial
Thursday, 12th December at 4:20 pm
Heavily-pretreated patients on lunresertib and camonsertib combination achieved 25.9% overall response rate (ORR) in endometrial cancer and 37.5% in platinum-resistant ovarian cancer
Nearly half of patients with gynecologic cancers maintained progression-free survival at 24 ...